Amneal Pharmaceuticals, Inc.
AMRX
$7.48
$0.060.81%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -19,823.72% | -102.60% | 106.54% | 7.10% | -1,118.89% |
| Total Depreciation and Amortization | 12.16% | 6.10% | 0.08% | -2.47% | -0.48% |
| Total Amortization of Deferred Charges | 1,734.49% | 54.45% | 223.96% | -93.83% | 97.54% |
| Total Other Non-Cash Items | -10.37% | 14.42% | -21.93% | -63.59% | 154.23% |
| Change in Net Operating Assets | -48.90% | 175.41% | -373.67% | -122.30% | 254.59% |
| Cash from Operations | -16.71% | 257.50% | 999.25% | -103.25% | 66.89% |
| Capital Expenditure | -31.28% | -59.87% | -6.40% | 14.69% | 5.48% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -100.00% | -- | -- | -- |
| Other Investing Activities | 83.33% | -380.00% | 92.27% | 51.26% | -1,890.00% |
| Cash from Investing | 22.47% | -220.37% | 67.28% | 37.65% | -135.17% |
| Total Debt Issued | -- | -- | -100.00% | -85.31% | 3,167.32% |
| Total Debt Repaid | 36.32% | -223.05% | 57.40% | 75.86% | -310.62% |
| Issuance of Common Stock | -75.53% | 72.35% | 1,178.57% | -34.88% | -89.46% |
| Repurchase of Common Stock | -99.48% | -22.01% | 97.80% | -4,523.08% | 17.46% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 2.27% | 32.94% | -1,295.45% | 99.64% | -401.77% |
| Cash from Financing | 33.72% | -163.20% | -51.53% | 77.04% | -16.45% |
| Foreign Exchange rate Adjustments | -10,671.43% | 106.93% | 38.79% | -182.09% | 166.78% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 39.52% | 1,539.75% | 95.80% | -1,456.86% | 118.45% |